Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 27, 2009

Immtech Considers an Alliance with Beijing Pharmaceutical

Immtech Considers an Alliance with Beijing Pharmaceutical

Possible alliance between Immtech and Beijing Pharmaceutical

  • Immtech Pharmaceuticals signed a memorandum of understanding (MOU) confirming its interest in exploring an alliance with Beijing Pharmaceutical (BPGC), which would grant the Chinese company rights to develop Immtech's drugs designed to target high-prevalence diseases. The companies will continue negotiations on the possible alliance pending BPGC's satisfactory review and valuation of Immtech's assets.

    The potential alliance would also give BPGC access to patented technologies from Immtech's international relationships as well as markets in the U.S., the Middle East, Africa, and Europe.

    "They are an ideal partner to draw on Immtech's extensive portfolio of compounds as well as our strong international network of collaborators in drug development and other business areas," says Eric L. Sorkin, chairman and CEO of Immtech.
    ADNFCR-2184-ID-19051078-ADNFCR



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »